SEC Comment Letter for Jade Biosciences, Inc. (JBIO) (CIK 0001798749) (JBIO) — May 13, 2026
Jade Biosciences, Inc. (JBIO) (CIK 0001798749)
Date: May 13, 2026 · CIK: 0001798749 · Accession: 0000000000-26-004877
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295665
Letter
May 13, 2026 Elizabeth Balta, Esq. Chief Legal Officer and Corporate Secretary Jade Biosciences, Inc. 221 Crescent St., Building 23, Suite 105 Waltham, MA 02453 Re: Jade Biosciences, Inc. Registration Statement on Form S-3 Filed May 07, 2026 File No. 333-295665 Dear Elizabeth Balta Esq.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew T. Bush, Esq.
Show Raw Text
May 13, 2026 Elizabeth Balta, Esq. Chief Legal Officer and Corporate Secretary Jade Biosciences, Inc. 221 Crescent St., Building 23, Suite 105 Waltham, MA 02453 Re: Jade Biosciences, Inc. Registration Statement on Form S-3 Filed May 07, 2026 File No. 333-295665 Dear Elizabeth Balta Esq.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew T. Bush, Esq.